Michael D. Pickard

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

Scott Kopetz, Axel Grothey, Rona Yaeger et al. · New England Journal of Medicine · 2019 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 1K citations · Full text

Medicine, Oncology, Pharmacology +11

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 586 citations

Medicine, Oncology, Pharmacology +11

Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular Events

Aileen M. Healy, Michael D. Pickard, Aruna D. Pradhan et al. · Circulation · 2006 · 336 citations · Full text

Medicine, Cardiology, Hematology +17

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma

Paolo A. Ascierto, Reinhard Dummer, Helen Gogas et al. · European Journal of Cancer · 2020 · 176 citations · Full text

Medicine, Clinical Sciences, Oncology +11